Cholestatic liver diseases result from impaired bile flow and are characterized by inflammation, atypical ductular proliferation, and fibrosis. The Wnt/b-catenin pathway plays a role in bile duct development, yet its role in cholestatic injury remains indeterminate. Liver-specific b-catenin knockout mice and wild-type littermates were subjected to cholestatic injury through bile duct ligation or short-term exposure to 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet. Intriguingly, knockout mice exhibit a dramatic protection from liver injury, fibrosis, and atypical ductular proliferation, which coincides with significantly decreased total hepatic bile acids (BAs). This led to the discovery of a role for b-catenin in regulating BA synthesis and transport through regulation of farnesoid X receptor (FXR) activation. We show that b-catenin functions as both an inhibitor of nuclear translocation and a nuclear corepressor through formation of a physical complex with FXR. Loss of b-catenin expedited FXR nuclear localization and FXR/retinoic X receptor alpha association, culminating in small heterodimer protein promoter occupancy and activation in response to BA or FXR agonist. Conversely, accumulation of b-catenin sequesters FXR, thus inhibiting its activation. Finally, exogenous suppression of b-catenin expression during cholestatic injury reduces b-catenin/FXR complex activation of FXR to decrease total BA and alleviate hepatic injury. Conclusion: We have identified an FXR/b-catenin interaction whose modulation through b-catenin suppression promotes FXR activation and decreases hepatic BAs, which may provide unique therapeutic opportunities in cholestatic liver diseases. (HEPATOLOGY 2018;67:955-971).
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C holestatic liver diseases are characterized by inflammation and fibrosis of bile ducts, cholangitis, cirrhosis, end-stage liver disease, and reduced life expectancy. Currently, there are few effective medical therapies available, and liver transplantation remains the only life-extending treatment option for many patients with end-stage cholestatic liver disease. Thus, the dearth of effective therapeutic strategies for managing chronic cholestasis is a major unmet clinical need. Additionally, the underlying pathophysiology of many cholestatic liver diseases is poorly understood despite extensive research. Recently, however, the "toxic bile" concept has been proposed as a major contributor in the pathogenesis of these conditions. This model postulates that cholestasis due to regurgitation of bile through leaky cholangiocyte junctions can Abbreviations: ADP, atypical ductular proliferation; ASO, antisense oligonucleotide; BA, bile acid; BDL, bile duct ligation; BSEP, bile salt export pump; ChIP, chromatin immunoprecipitation; Cyp, cytochrome P450; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; FXR, farnesoid X receptor; GalXC-CTNNB1, Dicer-substrate siRNA conjugated to N-acetylgalactosamine; IHC, immunohistochemistry; IP, immunoprecipitation; KO, knockout; MRP, multidrug resistance-associated protein; RXR, retinoic X receptor; SHP, small heterodimer partner; siRNA, small interfering RNA; TCF4, transcription factor 4; WB, western blot; WT, wild type. induce significant hepatocyte death and inflammation, leading to cholangitis and periductal fibrosis.
(1) Hepatocyte injury and death can occur due to either retention of high concentrations of bile acids (BAs) in the hepatocyte or abnormal BA composition consisting of a higher hydrophobic to hydrophilic ratio. (2) BAs also stimulate proliferation of atypical ductules that release both proinflammatory and profibrotic mediators, thus contributing to the disease process. (3) b-Catenin, the chief downstream effector of canonical Wnt signaling, has been shown to play an important role in liver development, hepatic metabolism and zonation, and liver regeneration. (4) b-Catenin also contributes to cholangiocyte differentiation during development and contributes to atypical ductular proliferation (ADP) in biliary injury models such as 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet. (5, 6) Additionally, recent studies have shown that liver-specific b-catenin conditional knockout (KO) mice exhibited modestly higher basal hepatic BAs than wild-type (WT) control mice, (7) likely due to sluggish bile flow. (8) Because both accumulation of BA and ADP are thought to contribute to the pathogenesis of cholestatic liver disease and loss of b-catenin alters BA homeostasis and suppresses ADP during injury, we hypothesized that modulation of b-catenin might impact cholestasis. In the current study, we subjected KO mice to two different models of cholestatic liver disease: bile duct ligation (BDL) and DDC diet. KO mice exhibited dramatically less liver injury, fibrosis, and ADP in the setting of cholestasis, which was attributable to decreased total hepatic BA levels. In fact, we uncovered a role of b-catenin in the regulation of BA synthesis and transport through its interactions with the farnesoid X receptor (FXR). We show that bcatenin functions both as an inhibitor of FXR nuclear translocation and as a nuclear corepressor through formation of a physical complex with FXR and that modulation of this complex may have therapeutic implications in cholestatic liver disease.
Materials and Methods
The generation of b-catenin KO mice has been described. (9) At 10-14 weeks of age, when b-catenin deletion is 100%, these mice and their WT littermates were subjected to BDL by dissecting the common bile duct above the pancreas and cutting it between two 5-0 silk ligatures.
Additional methods are available in the Supporting Information.
Results

LIVER-SPECIFIC b-CATENIN KO MICE ARE PROTECTED FROM HEPATIC INJURY, FIBROSIS, AND INFLAMMATION AFTER BDL
To characterize the role of b-catenin in cholestatic liver injury, KO and WT mice were subjected to BDL. Immunohistochemical (IHC) staining confirmed the absence of b-catenin in hepatocytes and cholangiocytes of KO mice (Fig. 1A) . While extensive biliary infarcts were visible throughout the hepatic lobules in the WT liver at 14 days after BDL, there was a significant lack Significantly fewer biliary infarcts in KO after BDL. ***P < 0.001. (D) No significant differences in overall survival between WT and KO after BDL. (E) Decreased serum markers of hepatic and biliary injury in KO at 14 days after BDL when compared to WT (n 5 5-6 per group). *P < 0.05, **P < 0.01, ***P < 0.001. Histological images are representative of more than four images per group. Bile infarct quantification and survival data obtained from n 5 8 animals/group. Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BR, bilirubin; GGTP, gamma-glutamyl transpeptidase; H&E, hematoxylin and eosin. of these lesions in KO mice (P 5 0.0002) (Fig. 1B,C) . A modest increase in mortality was observed in WT after 14 days of BDL, which was nonetheless insignificant (Fig. 1D) . We did not observe any differences in response to BDL in terms of mortality or morbidity when comparing male to female mice. Further, serum biochemistry from both groups of animals showed significantly lower levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transpeptidase in KO when compared to WT at 14 days after BDL (Fig. 1E) .
Because hepatic inflammation is a known contributor of injury in cholestatic liver disease, we next examined any differences in WT and KO after BDL. IHC for cluster of differentiation 45 showed enhanced inflammation around the periportal region in WT, which was notably lower in KO ( Fig. 2A ; Supporting  Fig. S1A ). Neutrophils extravasated into the parenchyma to infiltrate areas of necrosis in WT livers after BDL. In contrast, neutrophils are mainly present in the sinusoids of KO livers (Fig. 2B) . A notable decrease in number of cells positive for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling was also evident in KO compared to WT after BDL (Fig. 2C) .
Several alpha-smooth muscle actin-positive myofibroblasts were evident in WT and were conspicuously absent in KO livers after BDL (Supporting Fig. S1B ). This was concomitantly associated with a dramatic reduction in fibrosis in KO livers (Fig. 2D) , and lower liver weight to body weight ratios in KO compared to WT (Supporting Fig. S1C ). Extensive ductular reaction as identified by A6 immunofluorescence (5) was observed in WT livers after 14 days of BDL but was notably decreased in KO (Fig. 2E) . Cytokeratin 19 IHC confirmed that the number of intrahepatic bile ducts was greatly diminished in KO compared to WT (Supporting Fig. S1D ).
KO MICE HAVE A SIGNIFICANT DECREASE IN TOTAL HEPATIC BAs
We previously reported that KO livers exhibit modestly elevated BAs at baseline. (8) However, hepatic BAs fail to increase any further in KO after BDL, whereas in WT, BAs increased almost 6-fold (Fig.  3A) . Thus, in the setting of cholestasis, decreased hepatic injury and fibrosis in the absence of b-catenin appear to be due to decreased BA accumulation.
CHANGES IN BA SYNTHESIS, METABOLISM, AND TRANSPORTER GENES AFTER BDL
To examine the mechanism of decreased BAs in KO liver after BDL, we measured the expression of various BA transporters, biosynthesis, and metabolism genes after sham surgery or BDL. Measurement of the basolateral uptake transporter organic anion transporting polypeptide 4 shows a decrease in KO compared to sham, while Na 1 -taurocholate cotransporting polypeptide was unaffected (Fig. 3B) . However, apical transporters such as bile salt export pump (BSEP) and multidrug resistance-associated protein-2 (MRP2) are decreased in WT after BDL but increased in KO compared to sham (Fig. 3C) . BSEP is also increased in KO compared to WT after BDL (Fig. 3C) . Intriguingly, BA synthesis cytochrome P450 (Cyp) enzymes Cyp7a1 and Cyp27 are significantly lower in KO than in WT after BDL (Fig. 3D) . Conversely, Cyp3a11, which detoxifies hydrophobic BAs, (10) is increased many-fold in KO after BDL compared to WT (Fig. 3D) .
FXR, a BA-regulated nuclear receptor, regulates the expression of BSEP, MRP2, and Ostb and induces expression of small heterodimer protein (SHP), which inhibits Cyp7a1. (11) (12) (13) Gene expression analysis showed nonsignificant changes in FXR expression after BDL; however, SHP mRNA expression is dramatically increased in KO after BDL compared to WT (Fig. 3E) . Pregnane X receptor, a target of FXR that regulates Cyp3a11, is also higher in KO, (14) while fibroblast growth factor receptor 4, the receptor for fibroblast growth factor 15-mediated regulation of BA homeostasis, is unchanged (Fig. 3E) . Taken together, the response to cholestasis in the KO liver involves decreased synthesis of BAs and increased excretion of BAs from hepatocytes, with the net result being decreased accumulation of toxic BAs. Furthermore, increased activation of FXR may be the mechanism driving this process.
KO SHOWS A SIMILAR PROTECTION FROM SHORT-TERM DDC-INDUCED HEPATOBILIARY INJURY
To generalize our findings, we assessed another model of cholestatic liver injury and analyzed historical Immunofluorescence for A6 shows notably less ADP in KO after BDL compared to WT (3100). For (C), five representative 3100 images per animal (n 5 3 animals per group) were quantified; for (D), one to three representative 350 images per animal (n 5 7 animals per group) were quantified; for (E), five images per two representative animals per group were quantified. ****P < 0.0001. Abbreviations: CD, cluster of differentiation; TUNEL, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling.
samples from WT and KO mice after short-term DDC exposure. (5) Decreased fibrosis and hepatocellular injury were noted in KO livers after 28 days of a DDC diet (Supporting Fig. S2A ,B). Even though DDC does not induce BA accumulation to the same extent as BDL, total hepatic BAs were still modestly decreased in KO compared to WT after the DDC diet (Supporting Fig. S2C ). Additionally, although expression of BSEP and MRP2 is not induced after a DDC diet as it is after BDL, SHP expression is modestly increased; and a similar suppression of BA synthesis pathways and induction of detoxification were found in KO after 28 days of the DDC diet, as demonstrated by decreases in Cyp7a1 and Cyp27 and up-regulation of Cyp3a11 (Supporting Fig. S2D ). Thus, even though DDC and BDL cause cholestasis through distinct mechanisms, the absence of b-catenin offers protection in this alternate model of cholestasis, in part through amelioration of BA accumulation.
ABSENCE OF b-CATENIN INCREASES PROMOTER OCCUPANCY AND ACTIVATION OF FXR TARGET GENES
To further elucidate the effects of b-catenin on FXR activity, we performed chromatin immunoprecipitation (ChIP) on the SHP promoter, which is activated by FXR/retinoic X receptor alpha (RXRa) heterodimers. (12) The analysis demonstrates strong binding site occupancy by both FXR and RXRa in WT and KO before and after BDL (Fig. 4A,B) . Interestingly, we failed to see any evidence of increased FXR occupancy of SHP in a control animal after BDL at 14 days compared to baseline. To further corroborate these findings, we performed ChIP on very early time points after BDL in WT animals and again found no significant increases in FXR occupancy of the SHP promoter, despite BAs being acutely increased at these time points (Supporting Fig. S3A ). However, there was a modest but significant increase in FXR occupancy of the SHP promoter in KO after BDL compared to both KO at baseline and WT after BDL (Fig. 4A) . Furthermore, RXRa occupancy of the SHP promoter also increased in KO compared to WT after BDL (Fig. 4B) , which is likely due to increased occupancy of its binding partner, FXR, and not because of any direct association with bcatenin (data not shown). Together, these results suggest that absence of b-catenin during cholestasis increases nuclear translocation and association of the FXR/ RXRa complex on specific target genes.
To determine the specificity of this assay, we immunoprecipitated with antibody against constitutive androstane receptor, a nuclear receptor that plays a role in drug detoxification, (15) and found no changes in promoter occupancy of SHP in either genotype before or after BDL (Supporting Fig. S3B ). Interestingly, however, when ChIP was performed with transcription factor 4 (TCF4), the transcriptional partner for b-catenin, we noted a significant decrease in binding to the SHP promoter in both WT and KO after BDL (Fig. 4C) . Further analysis by ChIP sequencing revealed that TCF4 binds the SHP promoter on the same enhancer region as FXR and RXRa (Supporting Fig. S3C ). These data suggest that BAs trigger loss of TCF4 binding to the SHP promoter, which may be permissive of but not sufficient for transcriptional activation.
Finally, we examined H4K5 acetylation, a mark of transcriptional activation, (16) at the SHP promoter by ChIP. Activation at the SHP promoter was increased in b-catenin KO both at baseline and after BDL compared to time-matched WT controls (Fig. 4D) .
Taken together these findings suggest that increased FXR activation of SHP in KO after BDL is a combination of three factors: (1) increased FXR/RXRa binding and occupancy of the SHP promoter, due to absence of inhibitory b-catenin; (2) increased basal activity of the SHP promoter; and (3) loss of TCF4 in the presence of BAs, which may repress the transcriptional machinery at the SHP promoter.
FXR AGONIST INDUCES EARLIER NUCLEAR TRANSLOCATION IN b-CATENIN KO AND CONTRIBUTES TO A SYNERGISTIC INCREASE IN SHP REPORTER ACTIVITY IN VITRO
In order to further demonstrate that absence of bcatenin increases nuclear translocation of FXR, we next treated WT and KO mice with GW4064, an FXR agonist that induces acute and transient activation of FXR. (17) A dramatic increase in nuclear FXR occurs in the KO as early as 1 hour after GW4064 administration, while a comparable increase in nuclear FXR occurs in the WT at 3 hours (Fig. 5A) . ChIP also showed a shift to the left in FXR occupancy of the SHP promoter in KO (Fig. 5B) . This indicates that loss of b-catenin makes FXR amenable to earlier activation and that increased FXR nuclear translocation is one mechanism for the increased occupancy of SHP by FXR shown in our ChIP assay (Fig. 4) . Indeed, despite the fact that nuclear localization of FXR is not increased in KO at baseline (Fig. 5C ), IHC for FXR shows increased nuclear localization in the KO after BDL (Fig. 5D) .
We next used Hep3B hepatoma cells to determine the effect of b-catenin modulation on FXR in vitro. In contrast to liver, where FXR signaling is always active due to the presence of BAs, untreated Hep3B cells lack any basal FXR activity. Cotransfection with bcatenin small interfering RNA (siRNA) and SHP reporter plasmid led to a synergistic induction of SHP activity in the presence of GW4064 compared to similar treatment in control siRNA-transfected Hep3B cells (Fig. 5E ). On the other hand, treatment of Hep3B cells with ICG-001, a small molecule that inhibits b-catenin-cyclic adenosine monophosphate response element-binding protein association and thus antagonizes b-catenin-TCF4 transcriptional activity, (18) does not induce SHP reporter activity (Fig. 5F ). This is likely because inhibiting b-catenin transcription through ICG-001 does not decrease b-catenin protein levels but in fact increases the free pool of b-catenin in the cell (not shown). Thus, SHP activation was induced by diminishing b-catenin protein levels, while inhibiting its transcriptional activity was insufficient to promote SHP activation.
IDENTIFICATION OF AN FXR/b-CATENIN COMPLEX IN HEPATOCYTES
The above observations led us to examine if there was any physical interaction between b-catenin and FXR through immunoprecipitation (IP) studies using whole-cell lysates from WT, b-catenin KO, and FXR KO livers. Deletion of respective genes was confirmed by western blot (WB) and PCR (Fig. 6A) . IP of lysates with b-catenin antibody demonstrates an association of b-catenin with FXR in WT livers at baseline; notably, this interaction is absent in both b-catenin KO and FXR KO livers (Fig. 6B) . FXR IP using FXR antibody likewise showed association with b-catenin only in WT livers (Fig. 6C) .
Because changes in the association of FXR and bcatenin may alter the activation status of FXR, we next examined this relationship during cholestasis. Interestingly, we observed maintenance of the FXR/bcatenin complex in WT livers after BDL (Fig. 6D) . This may reflect a return to homeostatic conditions after chronic BA stimulation over a period of 14 days.
To support this hypothesis, we immunoprecipitated the FXR/b-catenin complex in Hep3B cells after short-term stimulation with either dimethyl sulfoxide or GW4064 and found a dramatic dissociation of FXR and b-catenin following GW4064 treatment (Fig.  6E) . Thus, this complex undergoes dynamic changes in the presence of BA or agonist and eventually reforms over time. As expected, FXR/b-catenin association is absent in KO mice both before and after BDL (Fig. 6D) . As a result of lack of b-catenin, FXR formed a complex more readily with RXRa in KO compared to WT after BDL (Fig. 6F) . Thus, the improved phenotype of the KO mice after BDL may be attributed to lack of inhibitory FXR/b-catenin association and the resulting increase in FXR/RXRa association.
MANIPULATION OF RXRa EXPRESSION ALTERS FXR/b-CATENIN ASSOCIATION
Next, we sought to determine if there was any evidence of competitive antagonism between b-catenin and RXRa for FXR. We confirmed RXRa overexpression and knockdown by WB and real-time PCR (Supporting Fig. S4A,B) . IP of Hep3Bs transfected with RXRa siRNA showed an increase in the amount of FXR/b-catenin association; conversely, overexpression of RXRa resulted in reduction of the FXR/b-catenin complex (Fig. 7A) . Thus, the amount of FXR bound to b-catenin can be altered by manipulating levels of RXRa in a cell.
MODULATION OF b-CATENIN IMPACTS FXR ACTIVITY IN VITRO
Hep3B cells were then transfected with b-catenin siRNA, which dramatically decreased b-catenin/Tcfdependent transcriptional activation (Supporting Fig.  S4C ). b-Catenin suppression decreased FXR/b-catenin association (Fig. 7B) ; intriguingly, this resulted in an increased amount of FXR bound to RXRa (Fig.  7C) . Additionally, Hep3B cells transfected with siRNA for b-catenin showed a significant increase in SHP reporter activity compared to control siRNA (Fig. 7D) . Finally, ChIP showed that in the presence of GW4064 FXR occupancy increases on the promoters of both SHP and Ostb, an ileal basolateral BA transporter that is expressed in human liver. (19) This increase also occurs following b-catenin suppression alone and is further augmented in the presence of concomitant GW4064 and b-catenin suppression (Fig.  7E) . Thus, lack of b-catenin in the cell enhances the affinity of FXR for RXRa, resulting in increased FXR activity.
We next transfected Hep3B cells with a plasmid containing a stable, nondegradable form of b-catenin (S33Y-b-catenin) (Supporting Fig. S4C ). FXR/b-catenin association increased notably in the presence of S33Y-b-catenin (Fig. 7B) , which decreased FXR/ RXRa association (Fig. 7C ). This coincided with an abrogation of SHP reporter activity in S33Y-transfected Hep3B cells compared to those transfected with a control plasmid (Fig. 7D) . Finally, overexpression of b-catenin led to a decrease in occupancy of the SHP and Ostb promoters by FXR (Fig. 7F) . Thus, b-catenin levels inversely correlated with FXR activation, with excess b-catenin sequestering FXR away from RXRa, resulting in suppression of downstream signaling.
b-CATENIN ANTISENSE OLIGONUCLEOTIDE DECREASES BA ACCUMULATION AND BILE INFARCTS AFTER BDL
To assess the effect of exogenous b-catenin suppression, WT mice were injected intraperitoneally with either 15 mg/kg EZN-3892 b-catenin antisense oligonucleotide (ASO; Santaris Pharma A/S) or EZN-3046 scrambled ASO at the same concentration every 48 hours for 2 weeks. Seven days after the first injection, mice were given BDL; and they were sacrificed at 12 days. Supporting Fig. S5A shows successful knockdown of b-catenin protein and signaling-as indicated by absent glutamine synthetase expression-by EZN-3892 after BDL. This led to a notable decrease in FXR/b-catenin association after b-catenin ASO treatment (Supporting Fig. S5C ), which was due to lack of b-catenin in hepatocytes (Supporting Fig. S5B ). As a consequence of abrogation of the b-catenin/FXR complex after EZN-3892 treatment, there was a significant reduction in liver total BA levels (Supporting Fig.  S5D ), although serum biochemistry was unchanged. Furthermore, SHP mRNA was increased following bcatenin inhibition, while indirect target Cyp7a1 was significantly suppressed (Supporting Fig. S5E ). Liver histology showed that b-catenin ASO-treated livers had significantly fewer bile infarcts after BDL than those treated with scrambled ASO (Supporting Fig.  S6A ). We next determined the extent of ADP by A6 and found that despite the continued presence of bcatenin in cholangiocytes (Supporting Fig. S5B ), bcatenin ASO-treated livers had quantifiably less ADP after BDL than their scrambled ASO counterparts (Supporting Fig. S6B ). Thus, mice receiving EZN-3892 had decreased b-catenin/FXR association, resulting in FXR activation, suppression of BA synthesis and accumulation, decreased hepatic injury, and improved intrahepatic cholestasis. To ensure reproducibility of our findings, we used b-catenin Dicer-substrate siRNA conjugated to Nacetylgalactosamine (Dicerna Pharmaceuticals; referred to hereafter as GalXC-CTNNB1), which confers the added benefit of specifically targeting RNA interference to hepatocytes. (20) Mice received one subcutaneous dose of GalXC-CTNNB1 or phosphate-buffered saline 3 days before BDL and weekly doses thereafter (Supporting Fig. S7A ). WB and IHC show successful knockdown of b-catenin protein in hepatocytes ( Fig.  8A; Supporting Fig. S7C ). Furthermore, both alkaline phosphatase and total liver BAs were significantly decreased in GalXC-CTNNB1-treated mice after BDL (Fig. 8B,C) , which corresponded with smaller bile infarcts (Fig. 8D) . SHP mRNA was modestly but significantly up-regulated in GalXC-CTNNB1-treated livers, while Cyp7a1 was dramatically repressed (Fig. 8E ). This coincided with increased FXR/RXRa association after GalXC-CTNNB1 treatment and BDL, simultaneously with decreased FXR/b-catenin association (Supporting Fig. S7B ). Finally, we performed analysis of BA composition in the liver and in bile from gallbladder. These results demonstrate a notable decrease in tauro-b-muricholic acid, a known FXR antagonist, in livers of GalXC-CTNNB1-treated mice after BDL (Fig. 8F) . (21) This resulted in a dramatic alteration of BA composition in both liver and gallbladder, from predominantly tauro-b-muricholic acid in control BDL to predominantly taurocholic acid in GalXC-CTNNB1-treated livers after BDL ( Fig.  8F; Supporting Fig. S7D ). We conclude that exogenous b-catenin inhibition not only increases total hepatic BA levels, leading to lesser injury, but also alters BA composition to a more favorable one, promoting further FXR activation.
Discussion
Wnt/b-catenin signaling regulates hepatobiliary repair in cholestatic injury models like the DDC diet. (5, 22) Here, we show that loss of b-catenin from liver confers protection after BDL, characterized by reduced BA pool, bile infarcts, fibrosis, inflammation, and ADP. In fact, we identify a FXR/b-catenin complex that regulates FXR activity during cholestasis and has a major impact on BA metabolism. Lack of bcatenin eliminates sequestration and corepression of FXR by b-catenin, leading to increased availability of FXR to recruit and bind RXRa, induce SHP, and in turn affect BA biosynthesis and stimulate its elimination (Supporting Fig. S8 ). These findings have identified a role of b-catenin in the progression of cholestatic diseases, thus providing an interventional opportunity.
We demonstrate that b-catenin negatively regulates FXR through direct binding. Indeed, b-catenin is also known to negatively regulate the activity of nuclear factor-jB through direct interaction. (23) Like nuclear factor-jB, FXR has been shown to be present in both the nucleus as well as the cytoplasm, where its activity is repressed by physical association with adenosine monophosphate-activated protein kinase. (24) Because b-catenin can also reside in both cellular compartments, we hypothesize two tandem mechanisms that lead to FXR activation in the absence or upon knockdown of b-catenin. We believe that b-catenin associates with FXR bound directly on the chromatin, preventing either ligand binding or RXRa association, and hence functions as a nuclear corepressor. It is unclear whether b-catenin continues to function as a corepressor in the WT after BDL as IP shows that the FXR/b-catenin complex persists despite activation of FXR target genes; it is possible that conformational changes in FXR due to BA binding may alter the complex, allowing for RXRa binding and transcriptional activation despite the continued presence of b-catenin. In the KO, however, the absence of b-catenin results in FXR-regulated transcription even at baseline, as supported by enhanced histone acetylation of SHP both before and after BDL in the KO; this transcriptional activation, however, may be compensated for at homeostasis by other mechanisms. The second mechanism is that of b-catenin acting as a negative regulator of FXR in the cytoplasm through physical association. Treatment with GW4064, a potent and selective FXR agonist, rapidly induces FXR nuclear translocation and SHP promoter occupancy earlier in the KO than in WT, indicating that a pool of inactive FXR may reside in the cytoplasm. This observation is further supported by increased FXR occupancy and recruitment of RXRa to the SHP promoter in the b-catenin KO after BDL. It was also intriguing to note the presence of a TCF4 binding site on the SHP promoter. Loss of TCF4 binding is permissive of FXR/RXRa binding on the SHP promoter to induce its histone acetylation and increased expression. However, TCF4 loss from the promoter is by itself not sufficient and likely requires a BA-driven FXR/RXRa occupancy of the promoter in order for increased transcription of SHP, which is facilitated by loss of b-catenin.
Despite increased expression of FXR target genes after BDL in WT, which was further enhanced in bcatenin KO, it was intriguing to note a minimal change of FXR or RXRa occupancy on the SHP promoter after BDL. Others have also reported lack of increased FXR occupancy on target gene promoters at either 3 or 7 days after BDL in both mice and rats. (25, 26) The lack of a clear change in occupancy is not entirely unexpected because FXR regulation of these genes is already highly active in normal basal liver. The findings are consistent with increased gene , which results in a higher percentage of taurocholic acid in these livers when expressed qualitatively as a percentage of total BA (right). *P < 0.05, **P < 0.01, ****P < 0.0001. Abbreviations: ALP, alkaline phosphatase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GS, glutamine synthetase; PBS, phosphate-buffered saline; TaMCA, tauro-a-muricholic acid; TbMCA, tauro-bmuricholic acid; TCA, taurocholic acid. expression because dynamic changes in nuclear receptor regulation of gene expression continue after binding to DNA, by modulation of corepression to coactivation, exchange of bound and unbound receptors, and degradation and replacement of bound receptors. (27) This cycling process, and gene activation, can be strongly affected by the concentration of receptors in the nucleus without a major change in total binding. Unlike constitutive occupancy of FXR on promoters of its targets in vivo, studies in Hep3B cells did show GW4064 to induce FXR occupancy at both SHP and Ostb promoters. Using this modulatable system, we identified a clear increase in FXR occupancy at both SHP and Ostb promoters following b-catenin suppression alone, which was further augmented by GW4064 treatment.
Because loss of b-catenin culminates in protection through activation of FXR and increased SHP expression, it is interesting to note that mice lacking FXR are counterintuitively protected from injury during BDL. (28) This is thought to be due to a decreased BA pool secondary to induction of MRP4, a negative target of FXR activation. However, FXR KO mice have an increased BA pool at baseline, and tissue-specific FXR KO models have elucidated the requirement of both liver and intestinal FXR in regulating BA synthesis through repression of Cyp7a1. (29) The importance of this regulation is illustrated in mice lacking SHP, which show increased sensitivity to BDL secondary to increased basal expression of Cyp7a1 and increased bile flow. (30, 31) The protective effect of SHP is also seen in several other studies where loss of SHP results in dysregulation of BA synthesis, while activation of SHP in hepatic stellate cells attenuates fibrosis. (32, 33) Thus, the increased SHP expression seen in b-catenin KO after BDL is in line with previous reports describing an improvement in phenotype through reduction of BA synthesis and metabolism.
Notably, FXR function could be altered by changing the number of FXR binding partners in the cell. Stable b-catenin secondary to mutations inhibited FXR and suppressed SHP activity compared to cells with nonmutant b-catenin, as did treatment with ICG-001, which increases the free pool of b-catenin in the cell. A recent study also showed that overexpression of an oncogenic form of b-catenin resulted in cholestasis. (34) Indeed, intratumoral cholestasis, a hallmark of hepatocellular carcinomas with stabilizing b-catenin gene mutations, (35) may be due to excessive levels of bcatenin that sequester FXR, making it unavailable to regulate BA levels. Additionally, we found that RXRa suppression led to increased FXR/b-catenin association, whereas its overexpression resulted in a notable decrease in FXR/b-catenin complex. We suggest that the inhibitory FXR/b-catenin complex antagonizes the transcriptionally active FXR/RXRa complex. Thus, the stoichiometric relationship between these three proteins in the cell may regulate FXR function. Furthermore, these complexes can be modulated to alter the ratio of active to inactive FXR, which may have important therapeutic implications.
The Wnt/b-catenin pathway plays a key role in establishing metabolic zonation in the liver. This pathway is constitutively active around the central vein, where it regulates expression of genes such as glutamine synthetase, Cyp1a2, and Cyp2e1. (36) Expression of Cyp7a1 and Cyp27 is also localized in the pericentral zone. (37) Thus, it is tempting to speculate that active b-catenin results in greater inhibition of FXR around the central vein, creating a permissive environment for BA synthesis through absence of Cyp7a1 and Cyp27 suppression. It should, however, be noted that a recent ChIP sequencing study identified Cyp27 to be a direct transcriptional target of b-catenin. (38) Thus, it is possible that b-catenin regulates BA homeostasis through both direct and indirect mechanisms.
Our studies also highlight the important role of BA accumulation in the formation of reactive ductules. The decreased ductular proliferation observed in bcatenin KO mice after BDL could be attributed to absence of b-catenin in cholangiocytes; alternatively, it could be secondary to decreased BA toxicity and cholestasis. However, our b-catenin ASO studies demonstrated conclusively that despite preservation of bcatenin expression in cholangiocytes, we still observed a significant suppression of ADP in b-catenin ASOtreated livers after BDL. Together, our findings indicate that ADP is not b-catenin-dependent and is the result of a compensatory reaction to increased BA, which supports our recent findings. (22) FXR agonists, which decrease BA biosynthesis and increase transport, have been touted as potential treatments for cholestatic liver diseases. (39) Indeed, a phase 3 clinical trial has demonstrated that the FXR agonist obeticholic acid, either alone or in combination with ursodeoxycholic acid, leads to a significant reduction in serum markers of liver injury and cholestasis in patients with primary biliary cholangitis. (40) However, this favorable outcome was associated with a high incidence of pruritus, which was dose-dependent and led to discontinuation of the drug in some patients. (41) Thus, while therapeutic targeting of FXR appears promising, the adverse effects associated with high dosage requirements underscore the need for more effective or combination therapies to treat cholestatic liver disease.
Suppression of b-catenin to target FXR/b-catenin association during cholestasis, which is an impediment to the formation of the FXR/RXRa complex, thus offers a therapeutic opportunity. Based on our findings, we expect that lower doses of FXR agonist will be required when combined with b-catenin suppression, increasing efficacy and reducing unwanted side effects. However, we are cognizant of the differences in the BA profiles between mice and humans, and it remains to be seen if b-catenin knockdown in patients would achieve the same favorable results. Additionally, although there are no b-catenin suppressive therapies currently used in clinical settings, our studies as well as others demonstrate efficacy in preclinical mouse models and provide a rationale for these targeted therapies.
